Mangalam Drugs & Organics (BOM:532637) Cyclically Adjusted Revenue per Share: ₹254.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532637 Mangalam Drugs & Organics Ltd BOM:532637
41 GF Score
Price ₹32.99
GF Value ₹62.93
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share?

Mangalam Drugs & Organics BOM:532637 +8.59% 41 Cyclically Adjusted Revenue per Share is ₹254.00 as of Jun. 2026. GuruFocus rates BOM:532637 with a GF Score™ of 41/100 and a GF Value™ of ₹62.93 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mangalam Drugs & Organics's adjusted revenue per share for the three months ended in Jun. 2026 was ₹36.117. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹254.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Mangalam Drugs & Organics's average Cyclically Adjusted Revenue Growth Rate was -0.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mangalam Drugs & Organics was 8.40% per year. The lowest was 1.80% per year. And the median was 5.50% per year.

As of today (2026-08-26), Mangalam Drugs & Organics's current stock price is ₹32.99. Mangalam Drugs & Organics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹254.00. Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio of today is 0.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mangalam Drugs & Organics was 0.90. The lowest was 0.09. And the median was 0.45.


Mangalam Drugs & Organics  (BOM:532637) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32.99/254.00
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mangalam Drugs & Organics was 0.90. The lowest was 0.09. And the median was 0.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Related Terms


Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 219.32 238.93 256.83 257.60 252.33

Mangalam Drugs & Organics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 256.36 256.70 253.69 252.33 254.00

BOM:532637 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangalam Drugs & Organics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio falls into.


BOM:532637
41GF Score
Mangalam Drugs & Organics Ltd BOM:532637
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mangalam Drugs & Organics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=36.117/167.3573*167.3573
=36.117

Current CPI (Jun. 2026) = 167.3573.

Mangalam Drugs & Organics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 48.040 105.961 75.875
201612 50.865 105.196 80.922
201703 52.332 105.196 83.255
201706 34.891 107.109 54.517
201709 52.501 109.021 80.594
201712 46.723 109.404 71.473
201803 42.445 109.786 64.703
201806 37.083 111.317 55.752
201809 45.355 115.142 65.923
201812 30.667 115.142 44.574
201903 27.987 118.202 39.626
201906 41.349 120.880 57.247
201909 42.468 123.175 57.701
201912 39.012 126.235 51.720
202003 55.628 124.705 74.654
202006 65.467 127.000 86.271
202009 61.257 130.118 78.789
202012 56.099 130.889 71.729
202103 57.145 131.771 72.578
202106 66.202 134.084 82.630
202109 72.129 135.847 88.860
202112 59.259 138.161 71.782
202203 85.062 138.822 102.547
202206 69.243 142.347 81.409
202209 67.368 144.661 77.938
202212 39.388 145.763 45.223
202303 56.883 146.865 64.820
202306 54.926 150.280 61.168
202309 51.491 151.492 56.883
202312 60.423 152.924 66.126
202403 63.226 153.035 69.143
202406 48.439 155.789 52.036
202409 50.402 157.882 53.427
202412 55.743 158.323 58.924
202503 49.008 157.552 52.058
202506 36.153 159.755 37.873
202509 31.113 162.289 32.085
202512 36.858 163.281 37.778
202603 42.519 164.272 43.317
202606 36.117 167.357 36.117

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹254.00 mean?
Mangalam Drugs & Organics (BOM:532637) has a Cyclically Adjusted Revenue per Share of ₹254.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' Cyclically Adjusted Revenue per Share too high?
Mangalam Drugs & Organics' current Cyclically Adjusted Revenue per Share is ₹254.00. Overall, Mangalam Drugs & Organics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Cyclically Adjusted Revenue per Share compare to ZTS?
Mangalam Drugs & Organics' Cyclically Adjusted Revenue per Share of ₹254.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Cyclically Adjusted Revenue per Share is ₹254.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (BOM:532637) is currently considered Possible Value Trap. The stock's GF Value™ is ₹62.93, compared to a current price of ₹32.99 — trading 47.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹254.00. Mangalam Drugs & Organics' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Mangalam Drugs & Organics (BOM:532637), the current Cyclically Adjusted Revenue per Share is ₹254.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (BOM:532637) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹32.99 is trading 47.6% below its estimated GF Value™ of ₹62.93. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for BOM:532637:

  • Cyclically Adjusted Revenue per Share: ₹254.00
  • GF Value™: ₹62.93 vs. price of ₹32.99 (47.6% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the BOM:532637 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mangalam Drugs & Organics Business Description

Other Exchanges MANGALAM:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
41GF Score

Get the complete analysis for BOM:532637

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹32.99
Price
₹62.93
GF Value